PUBLICATION

Engineering & Mining Journal

AUTHORS

Imara Salas, Laura Brangwin, Alfonso Tejerina

DOWNLOAD THE FULL PDF

Peru Mining 2017 E&MJ Release

Mining

Peru

August 07, 2017

After four consecutive years of shrinking exploration budgets, 2017 appears to be the turning point for the industry with drilling programs increasing again worldwide –and Peru is no exception. While some juniors learnt to navigate the low cycle through innovative business models, mostly aiming at generating cash-flow, those companies that managed to keep good assets are benefiting from much better market conditions to keep advancing their projects through the drill-bit. The Peruvian government has already unveiled its plans to simplify the regulatory framework for exploration which, coupled with more funds available in the market, should see the advancement of brand new projects to add to the country’s mining investment portfolio.

RELATED INTERVIEWS MORE INTERVIEWS

Raphael Khalifa

FOUNDER, TEMBO POWER

Tembo Power is developing hydropower projects across Africa with a focus on DRC.

CEO, CHESSER RESOURCES

Chesser Resources is upbeat about its Diamba Sud gold resource in Eastern Senegal.

Robocon speaks with GBR about the outlook for its services in Peru.

"Our product innovation process involves gathering client feedback and submitting it to the factory, which determines which ideas to pursue based on economic considerations."

Mining

Chile

B.C. Mining Enters an Era of Reconciliation

British Columbia Mining 2019 Pre-Release Edition

True cohesion between government, Indigenous groups and the sector is the priority.

Mining

Peru

Canada

The Global Tailings Standard

The mining industry and investment community are collaborating to mitigate a perpetual risk, after a series of high-profile disasters.

RECENT PUBLICATIONS

United States Life Sciences 2025 - Digital Interactive

Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.

MORE PREVIOUSLY PUBLISHED